3️⃣ The next challenge is patient selection.

Can neoantigen profiling, immune biomarkers, and ctDNA/MRD identify who benefits most?

And how should vaccination be positioned against neoadjuvant immunotherapy?

#PrecisionOncology #CancerVaccines
#ESMO2026 @myESMO